In Vitro Efficacy Testing Services for Usher Syndrome

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Usher syndrome. Our service specifically enables the evaluation of candidate compounds for their ability to modulate cellular processes implicated in Usher syndrome pathophysiology. Key targets include USH gene products such as myosin VIIA, harmonin, and cadherin 23, which are involved in the maintenance of photoreceptor and cochlear cell function. We assess pathological processes such as cell viability, apoptosis, and neurodegeneration relevant to the progression of sensory deficits in Usher syndrome.

Our testing portfolio includes quantitative dye-based cellular assays designed to rapidly measure cell viability and cytotoxicity in response to candidate therapeutics. These assays provide critical insight into the acute and longer-term cellular effects of treatment. By evaluating responses at multiple time points, we capture both immediate and delayed cellular outcomes.

Dye assay (DAPI) @ 2 h: This method utilizes DAPI staining to assess cell viability and nuclear integrity two hours after compound exposure, offering rapid evaluation of acute cytotoxic or protective effects.

Dye assay (DAPI) @ 24 h: By measuring DAPI staining at 24 hours post-treatment, this assay detects longer-term effects on cell survival and nuclear morphology, providing a more comprehensive assessment of compound efficacy and toxicity.

We measure critical pharmacological parameters that inform compound potency and therapeutic potential. These quantitative metrics enable precise comparison of candidate molecules and support informed decision-making during early-stage drug development.

EC-50: The half-maximal effective concentration (EC-50) represents the concentration of a compound required to achieve 50% of its maximum effect. This parameter is essential for ranking compound potency and determining optimal dosing ranges in preclinical development.

Recommended In Vitro Efficacy Tests

Clarin 1

Clarin 1 is a key protein implicated in Usher syndrome, a leading cause of combined deafness and blindness. Clarin 1 testing is crucial for drug development, enabling evaluation of compound efficacy in restoring protein function. The service uses DAPI dye assays at 2 and 24 hours to assess cellular response, with EC-50 determination as the primary parameter, providing quantitative insights into drug potency and therapeutic potential.